PTGS2 and squamous cell carcinoma: The knowledge provided by the present study could bring novel biomarkers of LSCC and other Head and Neck squamous cell carcinomas, and through exploration of the mechanisms of malignant transformation described in this research, novel therapeutic targets for LSCC, like COX2 inhibitors combined to already existing EGFR antibodies, could be developed in the future as strategies for treating this type of cancer.